Cystic fibrosis transmembrane conductance regulator-mRNA delivery: A novel alternative for cystic fibrosis gene therapy

Journal of Gene Medicine

Volumn 15, Issue 11-12, 2013, Pages 414-426

  Bangel Ruland, Nadine ^a   Tomczak, Katja ^a   Fernández Fernández, Elena ^a   Leier, Geraldine ^a   Leciejewski, Barbara ^a   Rudolph, Carsten ^b   Rosenecker, Joseph ^b   Weber, Wolf Michael ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cystic fibrosis; Functional restoration; Inherited disease; Ion transport

Indexed keywords

CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ELECTROPHYSIOLOGY; EPITHELIUM CELL; FEMALE; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NONHUMAN; OOCYTE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; WESTERN BLOTTING; XENOPUS LAEVIS;

CYSTIC FIBROSIS; FUNCTIONAL RESTORATION; INHERITED DISEASE; ION TRANSPORT;

ANIMALS; CELL LINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; OOCYTES; PRIMARY CELL CULTURE; RNA, MESSENGER; TRANSFECTION; XENOPUS LAEVIS;

EID: 84891091804     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2748     Document Type: Article

References (41)

1. Cuthbert AW. New horizons in the treatment of cystic fibrosis. Br J Pharmacol 2011; 163: 173-183.
2. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB. CFTR is a conductance regulator as well as a chloride channel. Phys Rev 1999; 79: S145-S166.
3. Guggino WB, Stanton BA. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 2006; 7: 426-436.
4. + conductance. Pflugers Arch 1996; 432: 516-522.
5. Kahl BC. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int J Med Microbiol 2010; 300: 514-519.
6. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073.
7. Mueller C, Flotte TR. Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol 2008; 35: 164-178.
8. Conese M, Ascenzioni F, Boyd AC, et al. Gene and cell therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros 2011; 10(Suppl 2): S114-S128.
9. Rosenecker J, Huth S, Rudolph C. Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr Opin Mol Ther 2006; 8: 439-445.
10. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549-551.
11. Conese M, Giola SD, Castellani S. Gene therapy for cystic fibrosis. Exp Opin Ther Patents 2008; 18: 929-943.
12. Davies G, Davies JC, Gill DR, et al. Safety and expression of a single dose of lipid-mediated Cftr gene therapy to the upper and lower airways of patients with cystic fibrosis. Thorax 2011; 66: A2.
13. Pearson H. One gene, twenty years. Nature 2009; 460: 164-169.
14. Lutz JF, Zarafshani Z. Efficient construction of therapeutics, bioconjugates, biomaterials and bioactive surfaces using azide-alkyne 'click' chemistry. Adv Drug Deliv Rev 2008; 60: 958-970.
15. Van Tendeloo VF, Ponsaerts P, Berneman ZN. mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 2007; 9: 423-431.
16. Kuhn AN, Diken M, Kreiter S, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010; 17: 961-971.
17. Kormann MS, Hasenpusch G, Aneja MK, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011; 29: 154-157.
18. Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108: 4009-4017.
19. + concentration on amiloride block and transport kinetics of rat ENaC expressed in Xenopus oocytes. Pflugers Arch 2002; 443: 882-891.
20. Blank U, Clauss W, Weber W-M. Effects of benzamil in human cystic fibrosis airway epithelium. Cell Physiol Biochem 1995; 5: 385-390.
21. Kusche-Vihrog K, Sobczak K, Bangel N, et al. Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pflugers Arch 2008; 455: 849-857.
22. Bangel-Ruland N, Sobczak K, Christmann T, et al. Characterization of the epithelial sodium channel delta-subunit in human nasal epithelium. Am J Respir Cell Mol Biol 2010; 42: 498-505.
23. Leier G, Bangel-Ruland N, Sobczak K, Knieper Y, Weber WM. Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Cell Physiol Biochem 2012; 29: 775-790.
24. Weber W-M, Clauss W, Cuppens H, Cassiman JJ, Van Driessche W. Capacitance measurements reveal different pathways for the activation of CFTR. Pflugers Arch 1999; 438: 561-569.
25. + permeability in cystic fibrosis human primary cell cultures. J Physiol (Lond) 1988; 405: 77-103.
26. - secretion in non-cystic fibrosis and cystic fibrosis human nasal epithelium. Cell Physiol Biochem 1999; 9: 1-11.
27. Bangel N, Dahlhoff C, Sobczak K, Weber WM, Kusche-Vihrog K. Upregulated expression of ENaC in human CF nasal epithelium. J Cyst Fibros 2008; 7: 197-205.
28. Kunzelmann K, Schreiber R. CFTR, a regulator of channels. J Membr Biol 1999; 168: 1-8.
29. Bradbury NA, Jilling T, Berta G, et al. Regulation of plasma membrane recycling by CFTR. Science 1992; 256: 530-532.
30. Bradbury NA, Jilling T, Kirk KL, Bridges RJ. Regulated endocytosis in a chloride secretory epithelial cell line. Am J Physiol 1992; 262: C752-C759.
31. Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1995; 271: 64-67.
32. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-236.
33. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-1065.
34. Drummond DR, Armstrong A, Colman A. The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes. Nucleic Acid Res 1985; 13: 7375-7394.
35. Yamamoto A, Kormann M, Rosenecker J, Rudolph C. Current prospects for mRNA gene delivery. Eur J Pharm Biopharm 2009; 71: 484-489.
36. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23: 165-175.
37. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007; 13: 1745-1755.
38. Anderson DM, Hall LL, Ayyalapu AR, et al. Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system. Hum Gene Ther 2003; 14: 191-202.
39. Zohra FT, Chowdhury EH, Nagaoka M, Akaike T. Drastic effect of nanoapatite particles on liposome-mediated mRNA delivery to mammalian cells. Anal Biochem 2005; 345: 164-166.
40. Rudolph C, Ortiz A, Schillinger U, et al. Methodological optimization of polyethylenimine (PEI)-based gene delivery to the lungs of mice via aerosol application. J Gene Med 2005; 7: 59-66.
41. Hasenpusch G, Geiger J, Wagner K, et al. Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles improve targeted drug and gene delivery to the lung. Pharm Res 2012; 29: 1308-1318.